Holen Sie sich die Stockscreener-App
3.86
5.46%
0.20
Handel nachbörslich:
3.90
0.04
+1.04%
Schlusskurs vom Vortag:
$3.66
Offen:
$3.7
24-Stunden-Volumen:
1.40M
Relative Volume:
1.18
Marktkapitalisierung:
$307.43M
Einnahmen:
$129.42M
Nettoeinkommen (Verlust:
$17.38M
KGV:
18.89
EPS:
0.2043
Netto-Cashflow:
$13.15M
1W Leistung:
+5.18%
1M Leistung:
-21.70%
6M Leistung:
-43.98%
1J Leistung:
-60.93%
1-Tages-Spanne:
$3.69
$4.04
1-Wochen-Bereich:
$3.565
$4.04
52-Wochen-Spanne:
$3.565
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.86 | 291.50M | 129.42M | 17.38M | 13.15M | 0.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims - The Manila Times
National Advertising Review Board Recommends Niagen Modify - GlobeNewswire
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower - Yahoo Finance
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy? - simplywall.st
Niagen Bioscience stock price target lowered to $11 by H.C. Wainwright - Investing.com Australia
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00 - MarketBeat
Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
A Look At Niagen Bioscience (NAGE) Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch - Sahm
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - Post Register
Q1 2026 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus? - Yahoo Finance
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results - Streetwise Reports
Niagen Bioscience Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences - BioSpace
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Sahm
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition By Investing.com - Investing.com South Africa
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com Canada
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Inc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce By Investing.com - Investing.com South Africa
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com UK
Niagen (NAGE) Q1 2026 Earnings Call Transcript - AOL.com
Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook - TipRanks
Niagen Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance - ChartMill
Niagen Bioscience Inc. (NAGE) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Niagen Bioscience: Q1 Earnings Snapshot - marketscreener.com
Niagen Bioscience (Nasdaq: NAGE) Q1 2026 sales reach $31.5M with strong margins - Stock Titan
Segment sale lifts Niagen Bioscience (Nasdaq: NAGE) Q1 2026 profit - Stock Titan
Tranche Update on Niagen Bioscience, Inc.'s Equity Buyback Plan announced on November 6, 2025. - marketscreener.com
Niagen Bioscience Is Maintained at Buy by Canaccord Genuity - Moomoo
Niagen Bioscience Price Target Cut to $10.00/Share From $13.00 by Canaccord Genuity - Moomoo
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Niagen Bioscience Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Launches Telehealth Platform for Home D - GuruFocus
Niagen Bioscience launches telehealth platform with at-home kit By Investing.com - Investing.com South Africa
Niagen Bioscience launches telehealth platform with at-home kit - Investing.com UK
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.81 |
4,465 |
30,406 |
7,372 |
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):